60 Degrees Pharmaceuticals, Inc.
SXTP
$1.75
-$0.11-5.91%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.80% | 100.80% | 579.53% | 585.23% | -60.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.80% | 100.80% | 579.53% | 585.23% | -60.18% |
| Cost of Revenue | 214.06% | 721.27% | 104.26% | -32.71% | 179.32% |
| Gross Profit | -334.21% | -840.71% | -45.99% | 45.67% | -204.84% |
| SG&A Expenses | -7.50% | 144.08% | 38.72% | 445.99% | 217.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.51% | 407.23% | 52.02% | 186.57% | 208.94% |
| Operating Income | -39.22% | -431.57% | -40.08% | -176.65% | -607.48% |
| Income Before Tax | -151.76% | -24.83% | 116.48% | -22.53% | 387.76% |
| Income Tax Expenses | 200.00% | 300.00% | 0.00% | 133.33% | -66.67% |
| Earnings from Continuing Operations | -151.77% | -24.84% | 116.48% | -22.55% | 387.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -92.78% | -78.57% | 200.00% | 727.78% | 203.13% |
| Net Income | -151.63% | -25.06% | 116.56% | -20.14% | 388.99% |
| EBIT | -39.22% | -431.57% | -40.08% | -176.65% | -607.48% |
| EBITDA | -39.44% | -438.99% | -41.26% | -178.86% | -627.53% |
| EPS Basic | -110.23% | 74.89% | 102.74% | 53.12% | 225.10% |
| Normalized Basic EPS | 74.02% | 64.07% | 104.68% | 55.61% | 53.21% |
| EPS Diluted | -110.23% | 74.89% | 102.74% | 53.12% | 225.10% |
| Normalized Diluted EPS | 74.02% | 64.07% | 104.68% | 55.61% | 53.21% |
| Average Basic Shares Outstanding | 445.11% | 412.63% | 339.43% | 143.22% | 125.45% |
| Average Diluted Shares Outstanding | 445.11% | 412.63% | 339.43% | 143.22% | 125.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
